Evommune executive exercises options, sells 20K shares

Evommune, Inc. Chief of Development Operations Janice Suzann Drew exercised stock options and sold shares in a planned trade.

Rhea-AI Filing Summary

Evommune, Inc. Chief of Development Operations Janice Suzann Drew exercised stock options and sold shares in a planned trade. On June 22, 2026, she exercised options to acquire a total of 20,000 shares of common stock at exercise prices of $2.99 and $3.84 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $22.63 per share.

The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026, indicating they were scheduled in advance. Footnotes also describe a standard multi-year vesting schedule for the underlying employee stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 20,000 shares ($390K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Drew Janice Suzann

Role Chief of Dev. Operations

Sold 20,000 shs ($453K)

Approx. gross sale proceeds $453K

Approx. exercise cost $63K

Approx. pre-tax spread $390K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	3,839	$0.00	$0.00
Exercise	Employee Stock Option (Right to Buy)	16,161	$0.00	$0.00
Exercise	Common Stock	3,839	$3.84	$15K
Exercise	Common Stock	16,161	$2.99	$48K
Sale	Common Stock	20,000	$22.63	$453K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 93,116 contracts (Direct); Common Stock — 67,794 shares (Direct)

Footnotes (3)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
3. F3. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Shares sold: 20,000 shares Sale price: $22.63 per share Options exercised at $2.99: 16,161 shares +2 more

5 metrics

Shares sold 20,000 shares Open-market sale of common stock on June 22, 2026

Sale price $22.63 per share Weighted average sale price for 20,000 shares

Options exercised at $2.99 16,161 shares Employee stock option exercise price $2.99 per share

Options exercised at $3.84 3,839 shares Employee stock option exercise price $3.84 per share

Net buy/sell shares -20,000 shares Transaction summary net buy/sell direction net-sell

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), vesting, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

vesting financial

"shares subject to the option shall vest in thirty-six (36) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 08:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drew Janice Suzann

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of Dev. Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		M(1)		3,839	A	$3.84	71,633	D
Common Stock	06/22/2026		M(1)		16,161	A	$2.99	87,794	D
Common Stock	06/22/2026		S(1)		20,000	D	$22.63(2)	67,794	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$3.84	06/22/2026		M(1)			3,839	(3)	05/11/2033	Common Stock	3,839	$0.00	53,795	D
Employee Stock Option (Right to Buy)	$2.99	06/22/2026		M(1)			16,161	(3)	12/08/2034	Common Stock	16,161	$0.00	39,321	D

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

3. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)